The ρ-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34+ CML progenitor cells

Leukemia

Volumn 21, Issue 8, 2007, Pages 1708-1714

  Burthem, J ^a,c   Rees Unwin, K ^a   Mottram, R ^b   Adams, J ^c   Lucas, G S ^c   Spooncer, E ^b   Whetton, A D ^b  

^a Stopford Building   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; BCR ABL PROTEIN; FASUDIL; IMATINIB; RHO KINASE; RHO KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CD34 SELECTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG POTENTIATION; EX VIVO STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; STEM CELL;

EID: 34447622126     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404762     Document Type: Article

References (25)

1. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11: 3425-3432.
2. Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, Kreil S et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 2005; 103: 1659-1669.
3. Unwin RD, Sternberg DW, Lu Y, Pierce A, Gilliland DG, Whetton AD. Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: Identification of the Rho pathway as a target of BCR/ ABL. J Biol Chem 2005; 280: 6316-6326.
4. DerMardirossian C, Bokoch GM. GDIs: Central regulatory molecules in Rho GTPase activation. Trends Cell Biol 2005; 15: 356-363.
5. Zhou H, Kramer RH. Integrin engagement differentially modulates epithelial cell motility by RhoA/ROCK and PAK1. J Biol Chem 2005; 280: 10624-10635.
6. Wiedemann A, Patel JC, Lim J, Tsun A, van Kooyk Y, Caron E. Two distinct cytoplasmic regions of the beta2 integrin chain regulate RhoA function during phagocytosis. J Cell Biol 2006; 172: 1069-1079.
7. Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA et al. BCR/ABL induces multiple abnormalities of cytoskeletal function: J Clin Invest 1997; 100: 46-57.
8. Bhatia R, Munthe HA, Verfaillie CM. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Exp Hematol 1999; 27: 1384-1396.
9. Nicholls SE, Lucas G, Graham GJ, Russell NH, Mottram R, Whetton AD et al. Macrophage-inflammatory protein-1alpha receptor expression on normal and chronic myeloid leukemia CD34+ cells. J Immunol 1999; 162: 6191-6209.
10. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
11. Saito H, Minamiya Y, Saito S, Ogawa J-i. Endothelial Rho and Rho kinase regulate neutrophil migration via endothelial myosin light chain phosphorylation. J Leukoc Biol 2002; 72: 829-836.
12. Bhatia R, Munthe HA, Williams AD, Zhang F, Forman SJ, Slovak ML. Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation. Exp Hematol 2000; 28: 1401-1412.
13. Melo JV, Deininger MW. Biology of chronic myelogenous leukemia - signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 2004; 18: 545-568.
14. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179-1187.
15. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
16. La Rosee P, Shen L, Stoffregen EP, Deininger M, Druker BJ. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/ Glivec). Hematol J 2003; 4: 413-419.
17. Croft DR, Olson MF. The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol 2006; 26: 4612-4627.
18. + cells. Br J Haematol 1998; 102: 759-767.
19. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792-3800.
20. Holtz MS, Slovak ML, Zhang F, Sawers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792-3800.
21. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E. Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005; 238: 31-39.
22. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive. cells. Blood 1997; 90: 3691-3698.
23. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
24. Michor F. Reply: The long-term response to imatinib-treatment of CML. Br J Cancer 2007; 96: 679-680.
25. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications. Nat Med 2006; 10: 1181-1184.